UCHL-3作为卵巢癌的潜在生物标志物
本研究通过生物信息学分析、体外实验和小鼠模型探索UCHL3在卵巢癌中的表达、预后价值及免疫效应,并构建UCHL3相关预后风险模型。UCHL3表达上调与更差的总生存相关,敲低UCHL3可抑制细胞增殖和迁移。UCHL3过表达与侵袭性进展、不良生存和铂类耐药相关,可能成为候选预后生物标志物和潜在治疗靶点。
要点
- UCHL3在卵巢癌中表达上调,与更差的总生存相关。
- 敲低UCHL3在体外和体内均抑制细胞增殖和迁移。
- UCHL3过表达与卵巢癌侵袭性进展、不良生存和铂类耐药相关。
核心结论
- UCHL3过表达促进卵巢癌侵袭性进展、不良生存和化疗耐药,可能作为候选预后生物标志物和潜在靶点。
研究设计与样本
- 研究采用生物信息学分析、CCK8和Transwell实验、小鼠模型验证、单因素和LASSO回归分析构建预后风险模型、GSEA和免疫分析、生物信息学分析和免疫组化。
主要发现
- UCHL3表达上调且与卵巢癌更差的总生存相关。
- UCHL3敲低在体外和体内均抑制细胞增殖和迁移。
- 高与低UCHL3表达组间有237个基因差异表达。
- 基于六个预后基因(PI3、TFAP2B、MUC7、PSMA2、PIK3C2G和NME1)构建了UCHL3相关预后特征。
- 独立预后分析提示年龄、肿瘤突变负荷和RiskScore可作为独立预后因素。
关键数值与推荐
- 免疫浸润分析和GSEA提示UCHL3表达与免疫反应相关。
- UCHL3表达在铂类耐药卵巢癌患者中高于铂类敏感患者。
- UCHL3过表达与更差的总生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study explored promising prognostic and immune therapeutic candidate biomarkers for OC and determined the expression, prognostic value, and immune effects of UCHL3. METHODS: UCHL3 expression and clinical data were investigated using bioinformatic analysis. CCK8 and transwell assays were conducted to evaluate the impact of UCHL3 on proliferation and migration, and the effects of UCHL3 were further validated in a mouse model. Univariate and least absolute shrinkage and selection operator regression analyses were performed to construct a novel UCHL3-related prognostic risk model. Gene set enrichment analysis (GSEA) and immune analysis were performed to identify the significantly involved functions of UCHL3. Finally, bioinformatic analysis and immunohistochemistry were performed to explore the effect of UCHL3 on chemotherapy. RESULTS: UCHL3 expression was upregulated and associated with worse overall survival (OS) in OC. UCHL3 depletion repressed cell proliferation and migration both in vitro and in vivo. Furthermore, 237 genes were differentially expressed between the high and low UCHL3 expression groups. Subsequently, a UCHL3-related prognostic signature was built based on six prognostic genes (PI3, TFAP2B, MUC7, PSMA2, PIK3C2G, and NME1). Independent prognostic analysis suggested that age, tumor mutational burden, and RiskScore can be used as independent prognostic factors. The immune infiltration analysis and GSEA suggested that UCHL3 expression was related to the immune response. In addition, UCHL3 expression was higher in platinum-resistant OC patients than in platinum-sensitive patients. UCHL3 overexpression was associated with poorer OS. CONCLUSION: UCHL3 overexpression contributes to aggressive progression, poor survival, and chemoresistance in OC. Therefore, UCHL3 may be a candidate prognostic biomarker and potential target for controlling progression and platinum resistance in OC.
引用
- Yang Q, Peng X, Nian Z, et al. UCHL-3 as a potential biomarker of ovarian cancer. Gynecol Oncol. 2024. PMID: 38266402. doi:10.1016/j.ygyno.2023.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。